Recent News for PSNL - Personalis, Inc.

Date Title
Nov 13 CSCO, TGP, BZH and Ping among notable after hour movers
Nov 13 Personalis EPS beats by $0.02, beats on revenue
Nov 13 Personalis Reports Third Quarter 2019 Financial Results
Nov 12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services
Nov 6 Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Nov 1 Here is What Hedge Funds Think About Personalis, Inc. (PSNL)
Oct 30 Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019
Oct 24 Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Oct 8 Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019
Sep 26 Personalis +5.8% on new $38M VA task order
Sep 26 MU, AMAT, LTM and SGH among notable after hour movers
Sep 26 Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M
Sep 26 24 Stocks Moving in Thursday's Pre-Market Session
Sep 20 What Kind Of Shareholder Owns Most Personalis, Inc. (NASDAQ:PSNL) Stock?
Sep 12 Personalis Appoints Karin Eastham to Its Board of Directors
Sep 9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Aug 26 Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 23 Personalis: Potential Growth Champion Has Much To Prove
Aug 15 61 Biggest Movers From Yesterday
Aug 14 Personalis, Inc. (PSNL) CEO John West on Q2 2019 Results - Earnings Call Transcript
Aug 13 Personalis EPS misses by $0.61, beats on revenue
Aug 13 Personalis Reports Second Quarter 2019 Financial Results
Aug 8 90 Biggest Movers From Yesterday
Aug 7 Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Aug 1 Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications
Back to the Main PSNL Page...